리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 11월
페이지 정보:영문 89 Pages
라이선스 & 가격 (부가세 별도)
한글목차
단일세포 게놈 시퀀싱 세계 시장은 2030년까지 72억 달러에 달할 전망입니다.
2023년에 29억 달러로 추정되는 단일 세포 게놈 시퀀싱 세계 시장은 분석 기간 2023-2030년에 CAGR 13.6%로 성장하여 2030년에는 72억 달러에 이를 것으로 예측됩니다. 분석한 부문 중 하나인 세포 게놈 시퀀싱 장비는 CAGR 14.2%로 성장을 지속하고, 분석 기간이 끝나면 45억 달러에 도달할 것으로 예측됩니다.
미국 시장은 8억 350만 달러로 추정, 중국은 CAGR 12.8%로 성장할 것으로 예측
미국의 단일 세포 게놈 시퀀싱 시장은 2023년 8억 350만 달러로 추정됩니다. 분석 기간(2023-2030년)중 CAGR는 12.8%로 예상됩니다.입니다. 기타 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 11.9%와 11.4%로 예측되고 있습니다.
세계의 단일 세포 게놈 시퀀싱 시장 - 주요 동향과 촉진요인 요약
단일 세포 게놈 시퀀싱는 유전체 조사를 어떻게 진행하고 있는가?
단일 세포 게놈 시퀀싱는 과학자가 개별 세포의 유전 물질을 분석 할 수있게 해주는 최첨단 기술이며, 세포의 이질성, 유전자 발현 및 질병 메커니즘에 대한 통찰력을 입자 크기 수준으로 제공 이 기술은 암의 진행, 면역 반응, 신경 질환, 발생 생물학 등의 복잡한 생물학적 시스템을 이해하는데 매우 중요합니다. 연구자들이 조직 내 유전적 돌연변이와 세포의 다양성을 확인할 수 있게 함으로써 단일 세포 게놈 시퀀싱은 질병 경로에 대한 보다 깊은 이해를 제공하고 보다 효과적인 진단, 표적 치료, 맞춤형 의료 접근으로 이어집니다. 정밀의료에 대한 수요가 높아지는 가운데, 단일 세포 게놈 시퀀싱는 유전체학 연구와 임상 응용에 혁명을 일으키고 있습니다.
단일 세포 게놈 시퀀싱 시장의 주요 부문은?
주요 기술로는 마이크로플루이딕스, 차세대 시퀀서(NGS), 정량 PCR 등이 있으며, 차세대 시퀀서는 높은 처리량, 정밀도, 종합적인 데이터 출력으로 최대 시장 점유율을 차지합니다. 용도는 암 유전체, 면역학, 줄기 세포 연구, 신경 생물학, 암 유전체학은 단일 세포 시퀀싱에 의해 종양 불균일성과 약물 내성에 대한 중요한 지식을 얻을 수 있기 때문에 중요한 부문을 차지하고 있습니다. 연구기관은 유전적 변이와 세포의 다양성 탐색에 중점을 두고 있기 때문에 시장을 주요 기업으로 삼고 있습니다.
단일 세포 게놈 시퀀싱는 연구 및 의료 분야에서 어떻게 사용됩니까?
암 연구에서 단일 세포 게놈 시퀀싱는 유전자 변이, 종양의 진화, 약물 내성 메커니즘의 동정에 사용되며, 표적 요법과 맞춤형 치료 전략의 개발을 지원하고 있습니다. 이를 이용하여 면역세포의 다양성을 이해하고, 면역반응을 추적하고, 자가면역질환이나 백신 개발을 위한 바이오마커를 확인하고 있습니다. 계통 추적, 재생 가능성 분석 및 조직 공학 및 재생 의학의 진보에 도움이 됩니다 신경 생물학에서 단일 셀 시퀀싱는 신경 발달 장애의 유전적 기반, 시냅스 기능, 뉴런의 다양성에 대한 통찰력을 얻을 수 있으며, 알츠하이머 병과 자폐증과 같은 질병에 대한 더 깊은 이해에 기여하고 있습니다. 또한, 단일 세포 시퀀싱의 임상 응용은 특히 정확한 유전자 프로파일 링이 중요한 출생 전 진단과 희귀질환의 특정에 확대되고 있습니다.
단일 세포 게놈 시퀀싱 시장의 성장을 가속하는 요인은?
단일 세포 게놈 시퀀싱 시장의 성장은 맞춤형 치료를 개발하기 위해 세포 수준의 상세한 유전자 정보에 의존하는 정밀의료에 대한 수요 증가와 같은 여러 요인에 의해 견인되고 있습니다., 정 학위 향상, 비용 절감과 같은 시퀀싱 기술의 발전으로 단일 세포 시퀀싱이 연구 및 임상 분야에서보다 쉽게 활용되고 있습니다. 포의 불균일성과 질병 메커니즘에 대한 통찰력을 얻을 수 있기 때문에 단일 세포 게놈 시퀀싱의 채용이 가속화되고 있습니다. 증가 이와 함께 시장의 성장을 더욱 촉진하고 있으며, 데이터 분석에 있어서 AI와 바이오인포매틱스의 통합은 복잡한 시퀀싱 데이터의 해석을 강화하고 유전체학 연구에 있어서 폭넓은 응용을 지원하고 있습니다.
조사 대상 기업 예(주목의 33사)
10x Genomics
Agilent Technologies, Inc.
BGI
Bio-Rad Laboratories
DNA Electronics Ltd.
F Hoffmann-La Roche Ltd.
Fluidigm
Illumina, Inc.
Johnson & Johnson
Novogene
Oxford Nanopore Technologies
Pacific Biosciences
QIAGEN
Thermo Fisher Scientific, Inc.
Zephyrus Biosciences Inc.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
JHS
영문 목차
영문목차
Global Single-Cell Genome Sequencing Market to Reach US$7.2 Billion by 2030
The global market for Single-Cell Genome Sequencing estimated at US$2.9 Billion in the year 2023, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2023-2030. Cell Genome Sequencing Instruments, one of the segments analyzed in the report, is expected to record a 14.2% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Cell Genome Sequencing Reagents segment is estimated at 12.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$803.5 Million While China is Forecast to Grow at 12.8% CAGR
The Single-Cell Genome Sequencing market in the U.S. is estimated at US$803.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 12.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.9% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.
Global Single-Cell Genome Sequencing Market - Key Trends and Drivers Summarized
How Is Single-Cell Genome Sequencing Advancing Genomics Research?
Single-cell genome sequencing is a cutting-edge technique that allows scientists to analyze the genetic material of individual cells, providing insights into cellular heterogeneity, gene expression, and disease mechanisms at a granular level. This technology is pivotal in understanding complex biological systems, including cancer progression, immune responses, neurological disorders, and developmental biology. By enabling researchers to identify genetic variations and cellular diversity within tissues, single-cell genome sequencing offers a deeper understanding of disease pathways, leading to more effective diagnostics, targeted therapies, and personalized medicine approaches. As the demand for precision medicine grows, single-cell genome sequencing continues to revolutionize genomics research and clinical applications.
What Are the Key Segments in the Single-Cell Genome Sequencing Market?
Key technologies include microfluidics, next-generation sequencing (NGS), and quantitative PCR, with next-generation sequencing holding the largest market share due to its high throughput, accuracy, and comprehensive data output. Major applications cover cancer genomics, immunology, stem cell research, and neurobiology, with cancer genomics representing a significant segment as single-cell sequencing provides critical insights into tumor heterogeneity and drug resistance. End-users encompass research institutes, clinical laboratories, and pharmaceutical companies, with research institutes leading the market due to their focus on exploring genetic variations and cellular diversity.
How Is Single-Cell Genome Sequencing Being Used Across Research and Medicine?
In cancer research, single-cell genome sequencing is used to identify genetic mutations, tumor evolution, and drug resistance mechanisms, supporting the development of targeted therapies and personalized treatment strategies. Immunology studies leverage single-cell sequencing to understand immune cell diversity, track immune responses, and identify biomarkers for autoimmune diseases and vaccine development. Stem cell research uses this technology to analyze cell differentiation, lineage tracing, and regenerative potential, aiding in advancements in tissue engineering and regenerative medicine. In neurobiology, single-cell sequencing provides insights into the genetic basis of neurodevelopmental disorders, synaptic functions, and neuron diversity, contributing to a better understanding of diseases like Alzheimer's and autism. Additionally, clinical applications of single-cell sequencing are expanding, particularly in prenatal diagnostics and rare disease identification, where accurate genetic profiling is crucial.
What Factors Are Driving the Growth in the Single-Cell Genome Sequencing Market?
The growth in the Single-Cell Genome Sequencing market is driven by several factors, including increasing demand for precision medicine, which relies on detailed genetic information at the cellular level to develop personalized treatments. Advancements in sequencing technologies, such as higher throughput, improved accuracy, and cost reductions, have made single-cell sequencing more accessible across research and clinical settings. The expanding focus on cancer genomics, immunotherapy, and neurodegenerative disease research has accelerated the adoption of single-cell genome sequencing, as it provides insights into cellular heterogeneity and disease mechanisms. Government funding and initiatives supporting genomics research, combined with growing collaborations between research institutes and pharmaceutical companies, have further fueled market growth. Additionally, the integration of AI and bioinformatics in data analysis has enhanced the interpretation of complex sequencing data, supporting broader applications in genomics research.
Select Competitors (Total 33 Featured) -
10x Genomics
Agilent Technologies, Inc.
BGI
Bio-Rad Laboratories
DNA Electronics Ltd.
F Hoffmann-La Roche Ltd.
Fluidigm
Illumina, Inc.
Johnson & Johnson
Novogene
Oxford Nanopore Technologies
Pacific Biosciences
QIAGEN
Thermo Fisher Scientific, Inc.
Zephyrus Biosciences Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Single-Cell Genome Sequencing - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Precision Medicine and Genomics Research Spurs Growth in Single-Cell Genome Sequencing Market
Technological Advancements in Sequencing Accuracy, Speed, and Data Analysis Strengthen Business Case for Adoption
Growing Focus on Cancer Genomics, Immunology, and Rare Disease Research Expands Addressable Market
Increasing Adoption of Sequencing in Stem Cell Research, Neuroscience, and Developmental Biology Expands Market Opportunities
Technological Innovations in Library Preparation, Microfluidics, and Bioinformatics Propel Market Expansion
Rising Focus on Complying with Ethical Guidelines, Informed Consent, and Data Privacy Drives Demand for Single-Cell Sequencing
Growing Use of Single-Cell Sequencing in Drug Discovery, Tumor Heterogeneity Studies, and Biomarker Discovery Expands Market Potential
Rising Adoption of Sequencing in Non-Invasive Prenatal Testing, Liquid Biopsies, and Cell-Free DNA Analysis Expands Addressable Market
Technological Advancements in AI-Powered Genomics, Machine Learning Algorithms, and Cloud Sequencing Propel Market Growth
Increasing Focus on Integrating Single-Cell Sequencing with Multi-Omics, CRISPR, and Synthetic Biology Drives Adoption
Rising Demand for Sequencing in Infectious Disease Genomics, Microbiome Research, and Immune Profiling Strengthens Global Market
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Single-Cell Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Single-Cell Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Academic & Research Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Academic & Research Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Academic & Research Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Biotech & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for qPCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 29: World Historic Review for qPCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 30: World 16-Year Perspective for qPCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Microarray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 32: World Historic Review for Microarray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 33: World 16-Year Perspective for Microarray by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for MDA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 35: World Historic Review for MDA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 36: World 16-Year Perspective for MDA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 37: World Single-Cell Genome Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
JAPAN
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Japan 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
CHINA
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 65: China Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: China Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: China 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
EUROPE
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Single-Cell Genome Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for Single-Cell Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
FRANCE
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 86: France Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: France Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: France 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
GERMANY
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Germany 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Italy 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
UNITED KINGDOM
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: UK Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: UK 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Europe Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Europe 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Europe Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Europe 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Europe Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Europe 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Asia-Pacific Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Asia-Pacific 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Asia-Pacific Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Asia-Pacific 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Asia-Pacific 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 140: Rest of World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of World Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of World 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
TABLE 143: Rest of World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of World Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of World 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
TABLE 146: Rest of World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of World Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of World 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030